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Abstract Despite the availability of
effective treatments, many migraine
sufferers in Europe still do not
receive optimal treatment. A panel
of specialists, primary-care physi-
cians and patient-group representa-
tives met in Rome on 10–11 June
2005, under the auspices of the
European Headache Federation
(EHF), the World Headache
Alliance (WHA) and the University
of Duisburg-Essen, to review the
scientific background, management
issues, and physician, patient and
government perspectives on
migraine. The goal of the meeting
was to produce the EHF/WHA
Rome Declaration on Migraine, a
statement of the actions required to
improve migraine care and the
quality of life of people with
migraine. The key recommendation
of the EHF/WHA Rome Declaration
on Migraine is education of
migraine sufferers, health profes-
sionals and health-policy makers.
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Migraine is a disabling neurological disorder of the brain
with potentially serious consequences that, in some
patients, extend widely beyond pain itself. Many aspects
of a sufferer’s life may be compromised by migraine,
including education, employment, personal relationships,
family life and social activities.
Despite the availability of effective treatments, many
people with migraine in Europe do not receive optimal
treatment. As recognition of the disabling effects of
migraine increases, a panel of headache specialists, pri-
mary care physicians and patient group representatives
from Europe, Canada, Israel, South Africa and the USA
gathered in Rome on 10–11 June 2005 for a Migraine
MetaForum. The meeting took place under the auspices
of the European Headache Federation (EHF), the World
Headache Alliance (WHA) and the University of
Duisburg-Essen. Its purpose was to review the scientif-
ic background, management issues, and physician,
patient and government perspectives on migraine. The
ultimate goal of the MetaForum was to arrive at a for-
mal consensus, expressed in the EHF/WHA Rome
Declaration on Migraine, comprising the issues, actions
and next steps required to improve migraine care and
quality of life among people affected by migraine in
Europe.
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The MetaForum panel aims to ensure that the findings
from the meeting and the Declaration are widely publi-
cised through the EHF, WHA and medical press, and used
to precipitate constructive change for migraine sufferers.
The continuing achievements of the Helsingborg
Declaration on Stroke Management [1], developed 10
years ago to improve the care of stroke patients, show that
such coordinated efforts are powerful politically. Most
goals of the Helsingborg Declaration have been achieved,
for example, to decrease mortality after stroke and to
implement dedicated stroke units.
The burden of migraine on society
Migraine is one of the most common neurological illness-
es, with around 12% of the adult population worldwide
suffering from migraine [2–11]. The World Health
Organization (WHO) has ranked migraine among the top
20 causes of disability, ahead of conditions such as asth-
ma and diabetes [12–14].
The impact of migraine on society includes its cumu-
lative effects on individuals, the direct costs of medical
treatment where these are borne by society and the indi-
rect costs of lost workdays and impairment at work, both
for people with migraine and for their family members. In
European and North American economic surveys, most of
the total costs of migraine were found to be attributable to
lost work productivity rather than the direct costs of
physician visits or medication [15, 16].
Effects of migraine on the affected individual
As well as the financial burden of migraine on health ser-
vices and employers, it is important not to underestimate
the impact of migraine on individuals. The Migraine and
its Effects on Life and Treatment (MELT) survey inter-
viewed 1810 women with migraine aged 18–35 years
from eight European countries and Israel, all of whom
were in full- or part-time work or full-time school or col-
lege, and were using headache medication [17, 18].
Participants experienced an average of 23 migraine or
other severe headaches per year, which in the previous 6
months had caused an average 2 days of absence and 4
days of reduced function at work or school [17]. As a
result, 16% of women reported that migraine had prevent-
ed them from achieving their career goals. Approximately
two-thirds of participants reported that migraine made
them less able to enjoy recreational or leisure activities.
Unsurprisingly, most women (86%) believed that their
lives would be better if they did not suffer from migraine.
Frustration, anger, depression and fear were commonly
reported negative emotions, with 23% afraid to leave the
house when anticipating a migraine attack [18].
The MELT study focused on the effects of migraine on
young women during a demanding phase of their lives,
when they were starting careers and families. Work loss
was greatest in the youngest women, in those who were
single, divorced, separated or widowed, and for women
with more frequent migraine attacks [17].
While 81% of participants had consulted a physician
during the previous year, 39% felt that their doctor did not
understand how much migraine interfered with their lives
[18]. Patients may understate the impact of migraine in
consultations with their physicians, especially if they have
not had an attack for some time, and should be encouraged
to keep a diary recording the longer-term consequences of
their attacks as well as the acute symptoms. Physicians
should ask not only about the severity of the pain, but also
about how migraine affects patients’ work or education,
family and social activities.
Migraine treatment strategies
Effective treatment requires that individual patients and
their physicians work together to develop a treatment plan
identifying specific and appropriate short-term goals [19].
Patients should be engaged in their management, for
example, by discussing treatment and medication prefer-
ences, and treatment should be tailored to each individ-
ual’s needs, based on frequency and severity of attacks,
degree of disability, associated symptoms, comorbid con-
ditions and prior response to medications.
Patients may be uncertain of the best time to take acute
migraine medication, delaying treatment until they are
sure they are having an attack or because they do not want
to use medication unless it becomes severe [20]. There is
evidence that acute treatment of migraine attacks with
triptans is most effective when taken early in the attack
while headache is mild rather than waiting until the pain
is more severe [21–25].
Multiple triptan studies have found that severe
migraine headache is more difficult to treat, which may
not be surprising. However, advising patients to treat
early in the attack has the potential disadvantage of
encouraging overuse of migraine medication and the
associated risks of inducing medication-overuse
headache. Indeed, an important goal of migraine manage-
ment is to prevent episodic migraine from transforming
into chronic headache. It is vital to educate patients to
avoid triggers and treat headaches appropriately, reduc-
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ing the risk of a chronic headache disorder. Patient edu-
cation includes understanding that acute medications
should not be used too frequently: triptans used regularly
on more than 10 days per month or simple analgesics on
more than 15 days per month can result in medication
overuse headache.
Evaluating the success of migraine treatments
The endpoints currently used in clinical trials may not be
ideal for assessing migraine treatment in clinical practice.
Questionnaires such as the Migraine Disability
Assessment (MIDAS), Headache Impact Test (HIT) and
Migraine Therapy Assessment Questionnaire (MTAQ) are
reliable and valid tools that provide valuable data in clin-
ical studies. However, such questionnaires may be too
complicated for patients and physicians to complete with-
in limited consultation time in primary care. Simple,
patient-friendly evaluation instruments are more practical
for use in primary care, both for initial assessment and as
a treatment outcome measure.
The most frequently used tools for the assessment of
migraine treatment success in clinical practice are
headache diaries or calendars. Patients should be instruct-
ed to record the date, duration, intensity and any trigger-
ing factors of each attack, and the medications used to
treat it. The physician can then use the diary to assess
migraine severity and impact on daily life, and success of
current treatment, and plan future follow-up.
In everyday clinical practice, reappraisal of treatment
success should be routine and repeated from time to time,
as migraine characteristics and patients’ treatment needs
can evolve.
Consensus of the MetaForum: the EHF/WHA Rome
Declaration on Migraine
With the great diversity and depth of experience and
knowledge among the participants, the MetaForum panel
has drawn together a unique view of the key issues and
developed goals and action points for the EHF/WHA
Rome Declaration on Migraine that will improve out-
comes for patients with migraine. The key recommenda-
tion to come out of the meeting was education of people
affected by migraine, health professionals who treat
migraine and health-policy makers. The MetaForum panel
was unanimous in its hope that the EHF/WHA Rome
Declaration on Migraine will improve quality of life
greatly for migraine sufferers.
The EHF/WHA Rome Declaration on Migraine: Migraine
“The Forgotten Epidemic”: A European Perspective
Consensus statements
- Migraine is a neurovascular disorder of the brain.
- The WHO recognises that migraine is the 12th highest
cause of disability in women and the 19th highest
cause of disability amongst both sexes:
- it affects approximately 50 million people in
Europe;
- every day nearly 2 million Europeans have a
migraine attack;
- it costs the European economy well over 10 bil-
lion every year.
- A range of effective treatments exist. Acute therapy
reduces disability during the attack and preventative
therapy can reduce the frequency and severity on a
long-term basis.
- Failure of healthcare systems to provide effective
treatments to those who need them is the most impor-
tant reason why this socio-economic burden persists.
- We call upon the governments and health policy mak-
ers of Europe to:
- match our commitment to people affected by
migraine;
- recognise the priority that migraine deserves;
- provide the resources that these initiatives require.
- We would like to emphasise that the cost of these
resources will be offset by recovered work productivity.
Consensus actions
- Over the next 5 years, these are the targets we wish to
achieve in Europe:
- the percentage of migraine patients in the care of a
physician should increase from the current level of
30% to 50%;
- the number of patients receiving effective therapy
for acute migraine attacks should increase from the
current level of 40% to 70%;
- at least 50% of patients requiring migraine preven-
tion therapy should be receiving this treatment.
- We will work with the WHO on their public-health
report, which will publish the trends and burden of
migraine including:
- collation of national data on risk factors, incidence
and prevalence;
- a clear definition of the burden of migraine (both
direct and indirect costs) and a definitive report on
the associated health economics;
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- the need to screen for conditions co-morbid with
migraine and to help patients’ understanding that
migraine can lead to co-morbid states.
- By working together, the professional and patient
organisations active in Europe will:
- set up awareness initiatives for the general public
in order to create recognition of the need for treat-
ment of migraine;
- set up educational programmes for healthcare
providers in order to improve their ability to diag-
nose and treat migraine;
- produce and disseminate diagnostic aids, management
guidelines and instruments for outcome evaluation.
- To achieve this, we will:
- publish a literature review on current knowledge,
perception and attitude of physicians and patients
as a first step in awareness and improving the treat-
ment of migraine across Europe;
- develop active communication between patient
organisations, healthcare providers and govern-
ments on migraine, its disabling effects, its public-
health importance and its management;
- promote use of tools that increase the knowledge of
physicians, support them and sustain their compli-
ance with nationally established guidelines;
- challenge governments and health-policy makers to
promote programmes to diminish the social and
economic burdens of migraine;
- urge physicians to encourage their patients to com-
municate freely their personal concerns and experi-
ences in order to understand the true impact of the
disorder;
- apply measures of outcome to optimise acute and
preventive migraine therapy.
- We will monitor the effects of these initiatives to
demonstrate beneficial change.
This declaration is reproduced with permission from the
EHF and WHA. Reproduction of this material without
permission from the EHF and WHA is prohibited.
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